$48 million was raised by Seres Health following the successful placement and issuance of its unregistered equity securities. A total of twenty investors participated to the non-brokered placement which started a little over a week ago. Until this disclosure Seres Health had raised an estimated $10.63 million in unregistered securities via one previous financing round.
Seres Health develops Ecobiotic therapeutic products, novel drugs to treat important diseases by targeting the underlying biology of the human microbiome. The company is backed by VentureLabs, Flagship Ventures’ innovation foundry.
The company, headquartered in Cambridge MA, is led by Roger J Pomerantz (President and CEO). Seres Health elected to keep its revenues undisclosed.
The executive team includes David Cook, Eric D Shaff and John Aunins.
The board of directors includes David Berry, Lorence Kim, Noubar Afeyan, Peter Barton Hutt, Richard Kender and Werner Cautreels.
The company has raised an estimated total of $58.63 million via private unregistered security offerings.
Company: Seres Health
Amount offered: $48 million
Amount placed: $48 million
SEC filing: Source
First sale: 11-24-2014
Data as of: 12-02-2014